Skip to Main content Skip to Navigation
Journal articles

C3 glomerulonephritis in a patient treated with anti–PD-1 antibody

Simon Ville 1, 2 Christine Kandel-Aznar 3 Veronique Fremeaux-Bacchi 4, 5 Fadi Fakhouri 1, 2
1 U1064 Inserm - CRTI - Centre de Recherche en Transplantation et Immunologie
2 ITUN - Institut de transplantation urologie-néphrologie
3 CHU Nantes - Centre hospitalier universitaire de Nantes
4 Laboratoire d'Immunologie Biologique
5 CRC (UMR_S_1138 / U1138) - Centre de Recherche des Cordeliers
Abstract : Immune checkpoint inhibitors (ICIs) have dramati-cally transformed the treatment of solid tumors. ICIsinduce an immune response against tumoral cells as aresult of the removal of T-cell inhibition [1]. The logicalcounterpart of turning off T-cell inhibitory mechanismsis the onset of immune-related adverse events (irAEs)that affect different organs. Although the most frequentrenal irAE is acute interstitial nephritis [2], we report afirst case of C3 glomerulonephritis (GN) associated withthe use of an antieProgrammed Cell Death 1 (PD-1)humanised antibody.
Complete list of metadatas
https://www.hal.inserm.fr/inserm-02449014
Contributor : Ana Paula Dutra Azevedo <>
Submitted on : Wednesday, January 22, 2020 - 4:03:35 PM
Last modification on : Saturday, March 28, 2020 - 1:55:43 AM

Identifiers

Collections

UNIV-NANTES | CRTI | SORBONNE-UNIVERSITE | CORDELIERS | EPHE | PSL | SU-SCIENCES

Citation

Simon Ville, Christine Kandel-Aznar, Veronique Fremeaux-Bacchi, Fadi Fakhouri. C3 glomerulonephritis in a patient treated with anti–PD-1 antibody. European Journal of Cancer, Elsevier, 2020, 125, pp.46-48. ⟨10.1016/j.ejca.2019.11.011⟩. ⟨inserm-02449014⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

86

Contact

Informations

CCSD